The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature
BackgroundHepatocellular carcinoma (HCC) is a highly lethal and invasive cancer. Targeted and immunotherapies are the primary treatment options for unresectable advanced HCC. There are no recognized and consistent systemic follow-up treatments for patients with HCC who experience disease progression...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1461936/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846162621088137216 |
|---|---|
| author | Tao Li Ying Zhao Keren Li Gong Li Guangxin Li |
| author_facet | Tao Li Ying Zhao Keren Li Gong Li Guangxin Li |
| author_sort | Tao Li |
| collection | DOAJ |
| description | BackgroundHepatocellular carcinoma (HCC) is a highly lethal and invasive cancer. Targeted and immunotherapies are the primary treatment options for unresectable advanced HCC. There are no recognized and consistent systemic follow-up treatments for patients with HCC who experience disease progression after first-line targeted therapies and immune checkpoint inhibitors (ICIs). According to a few studies, lenalidomide is an immunomodulatory drug that has the potential to be an effective treatment for patients who have progressed after treatment with targeted drugs and ICIs.Case summaryThis article focuses on a patient with HCC whose disease progressed after first-line targeted therapy and ICI therapy combined with lenalidomide as second-line therapy on the basis of the original targeted and ICI regimens, resulting in a favorable oncologic outcome with acceptable toxicity. The progression-free survival (PFS) of the patients in this study reached 3 years, which is much longer than that previously reported, and no progression has occurred thus far.ConclusionsThis case implies that in patients with hepatocellular carcinoma who have failed first-line targeted therapy and ICIs, targeted therapy and ICIs can be restarted with the addition of lenalidomide, with surprising results. |
| format | Article |
| id | doaj-art-760e1b66a5004f4f8227915ebf6e6695 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-760e1b66a5004f4f8227915ebf6e66952024-11-20T05:10:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14619361461936The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literatureTao LiYing ZhaoKeren LiGong LiGuangxin LiBackgroundHepatocellular carcinoma (HCC) is a highly lethal and invasive cancer. Targeted and immunotherapies are the primary treatment options for unresectable advanced HCC. There are no recognized and consistent systemic follow-up treatments for patients with HCC who experience disease progression after first-line targeted therapies and immune checkpoint inhibitors (ICIs). According to a few studies, lenalidomide is an immunomodulatory drug that has the potential to be an effective treatment for patients who have progressed after treatment with targeted drugs and ICIs.Case summaryThis article focuses on a patient with HCC whose disease progressed after first-line targeted therapy and ICI therapy combined with lenalidomide as second-line therapy on the basis of the original targeted and ICI regimens, resulting in a favorable oncologic outcome with acceptable toxicity. The progression-free survival (PFS) of the patients in this study reached 3 years, which is much longer than that previously reported, and no progression has occurred thus far.ConclusionsThis case implies that in patients with hepatocellular carcinoma who have failed first-line targeted therapy and ICIs, targeted therapy and ICIs can be restarted with the addition of lenalidomide, with surprising results.https://www.frontiersin.org/articles/10.3389/fonc.2024.1461936/fullhepatocellular carcinoma (HCC)lenalidomideimmunomodulatory drugmetastasescase report |
| spellingShingle | Tao Li Ying Zhao Keren Li Gong Li Guangxin Li The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature Frontiers in Oncology hepatocellular carcinoma (HCC) lenalidomide immunomodulatory drug metastases case report |
| title | The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature |
| title_full | The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature |
| title_fullStr | The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature |
| title_full_unstemmed | The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature |
| title_short | The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature |
| title_sort | survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second line therapy a case report and review of the literature |
| topic | hepatocellular carcinoma (HCC) lenalidomide immunomodulatory drug metastases case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1461936/full |
| work_keys_str_mv | AT taoli thesurvivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT yingzhao thesurvivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT kerenli thesurvivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT gongli thesurvivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT guangxinli thesurvivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT taoli survivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT yingzhao survivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT kerenli survivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT gongli survivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature AT guangxinli survivalandsafetyofmetastatichepatocellularcarcinomatreatedwithlenalidomideassecondlinetherapyacasereportandreviewoftheliterature |